126 related articles for article (PubMed ID: 34028367)
21. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study.
Dublin S; Walker RL; Jackson ML; Nelson JC; Weiss NS; Jackson LA
Pharmacoepidemiol Drug Saf; 2010 Aug; 19(8):792-802. PubMed ID: 20623507
[TBL] [Abstract][Full Text] [Related]
22. Histamine-2-receptor antagonists and oesophageal cancer.
Fioretti F; Tavani A; La Vecchia C; Franceschi S
Eur J Cancer Prev; 1997 Apr; 6(2):143-6. PubMed ID: 9237063
[TBL] [Abstract][Full Text] [Related]
23. Ranitidine Use and Gastric Cancer Among Persons with Helicobacter pylori.
Kumar S; Goldberg DS; Kaplan DE
Dig Dis Sci; 2022 May; 67(5):1822-1830. PubMed ID: 33856609
[TBL] [Abstract][Full Text] [Related]
24. Statin use and the risk of bladder cancer: a population-based case-control study.
Kuo CC; Chiu HF; Lee IM; Kuo HW; Lee CT; Yang CY
Expert Opin Drug Saf; 2012 Sep; 11(5):733-8. PubMed ID: 22849562
[TBL] [Abstract][Full Text] [Related]
25. Acetaminophen and the risk of renal and bladder cancer in the general practice research database.
Kaye JA; Myers MW; Jick H
Epidemiology; 2001 Nov; 12(6):690-4. PubMed ID: 11679798
[TBL] [Abstract][Full Text] [Related]
26. Comparison of fracture risk between proton pump inhibitors and histamine-2 receptor antagonists in ANCA-associated vasculitis patients: a nested case-control study.
Miyano S; Michihata N; Sada KE; Uda K; Matsui H; Fushimi K; Nangaku M; Yasunaga H
Rheumatology (Oxford); 2021 Apr; 60(4):1717-1723. PubMed ID: 33067623
[TBL] [Abstract][Full Text] [Related]
27. Association between use of acid-suppressive drugs and risk of gastric cancer. A nested case-control study.
Tamim H; Duranceau A; Chen LQ; Lelorier J
Drug Saf; 2008; 31(8):675-84. PubMed ID: 18636786
[TBL] [Abstract][Full Text] [Related]
28. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study.
Robertson DJ; Larsson H; Friis S; Pedersen L; Baron JA; Sørensen HT
Gastroenterology; 2007 Sep; 133(3):755-60. PubMed ID: 17678921
[TBL] [Abstract][Full Text] [Related]
29. Histamine-2-receptor antagonists and gastric cancer: update and note on latency and covariates.
La Vecchia C; Negri E; Franceschi S; D'Avanzo B
Nutrition; 1992; 8(3):177-81. PubMed ID: 1356031
[TBL] [Abstract][Full Text] [Related]
30. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
[TBL] [Abstract][Full Text] [Related]
31. Occupational contact allergy to omeprazole and ranitidine.
Herrera-Mozo I; Sanz-Gallen P; Martí-Amengual G
Med Pr; 2017 May; 68(3):433-435. PubMed ID: 28512370
[TBL] [Abstract][Full Text] [Related]
32. Hypersensitivity reaction to ranitidine: description of a case and review of the literature.
Foti C; Cassano N; Panebianco R; Calogiuri GF; Vena GA
Immunopharmacol Immunotoxicol; 2009; 31(3):414-6. PubMed ID: 19694603
[TBL] [Abstract][Full Text] [Related]
33. A case-control study of smoking and bladder cancer risk: emergent patterns over time.
Baris D; Karagas MR; Verrill C; Johnson A; Andrew AS; Marsit CJ; Schwenn M; Colt JS; Cherala S; Samanic C; Waddell R; Cantor KP; Schned A; Rothman N; Lubin J; Fraumeni JF; Hoover RN; Kelsey KT; Silverman DT
J Natl Cancer Inst; 2009 Nov; 101(22):1553-61. PubMed ID: 19917915
[TBL] [Abstract][Full Text] [Related]
34. Effects of ranitidine and nizatidine on the risk of gastrointestinal cancer.
Kang H; Nam CM; Choi DW; Park S
Front Oncol; 2023; 13():1182174. PubMed ID: 37576886
[TBL] [Abstract][Full Text] [Related]
35. Proton-pump inhibitor use and the risk for community-acquired pneumonia.
Sarkar M; Hennessy S; Yang YX
Ann Intern Med; 2008 Sep; 149(6):391-8. PubMed ID: 18794558
[TBL] [Abstract][Full Text] [Related]
36. Ranitidine-induced black tongue: A case report.
Akcaboy M; Sahin S; Zorlu P; Şenel S
Pediatr Dermatol; 2017 Nov; 34(6):e334-e336. PubMed ID: 28967681
[TBL] [Abstract][Full Text] [Related]
37. An antibody from a patient with ranitidine-induced thrombocytopenia recognizes a site on glycoprotein IX that is a favored target for drug-induced antibodies.
Gentilini G; Curtis BR; Aster RH
Blood; 1998 Oct; 92(7):2359-65. PubMed ID: 9746775
[TBL] [Abstract][Full Text] [Related]
38. A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients.
Avşar E; Tiftikçi A; Poturoğlu S; Erzin Y; Kocakaya O; Dinçer D; Yıldırım B; Güliter S; Türkay C; Yılmaz U; Onuk MD; Bölükbaş C; Ellidokuz E; Bektaş A; Taşan G; Aytuğ N; Ateş Y; Kaymakoğlu S
Turk J Gastroenterol; 2013; 24(4):316-21. PubMed ID: 24254262
[TBL] [Abstract][Full Text] [Related]
39. [Are proton pump inhibitors superior to H2 receptor antagonists within the scope of H. pylori eradication therapy? Meta analysis of current parallel group comparisons].
Holtmann G; Layer P; Goebell H
Z Gastroenterol; 1996 May; 34(5):267-72. PubMed ID: 8686357
[TBL] [Abstract][Full Text] [Related]
40. Mania associated with ranitidine: a case report and review of literature.
Mauran A; Goze T; Abadie D; Bondon-Guitton E; Chevrel P; Schmitt L; Montastruc JL; Montastruc F
Fundam Clin Pharmacol; 2016 Aug; 30(4):294-6. PubMed ID: 27083385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
